Pharmaceuticals News and Research

RSS

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases.

1 Oct 2009

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Cutting Edge Information hopes to see ill patients have speedier access to potential cures

The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.

1 Oct 2009

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.

1 Oct 2009

USPTO allows BioMarin's claims covering the approved administration of sapropterin dihydrochloride with food

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the United States Patent and Trademark Office has allowed claims covering the approved administration of Kuvan® (sapropterin dihydrochloride) with food, based on the discovery that food increases the bioavailability of Kuvan. The company expects that the patent, which expires in 2024, will officially issue later this year.

1 Oct 2009

PharmaNova to announce new technology breakthroughs at the 2009 AAPS annual meeting

PharmaNova, a leader in nanotechnology-based Drug Delivery Systems, is due to exhibit at the 2009 annual meeting of the American Association of Pharmaceutical Scientists (AAPS) scheduled in Los Angeles, CA, from November 8 - 12.

1 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

Society of Interventional Radiology offers intensive five-day course

The Society of Interventional Radiology presents Catheter Lysis of Thromboembolic Stroke (CLOTS)-an intensive five-day course featuring top interventional radiologists, neurointerventionists, neurologists and neuroradiologists offering doctors the opportunity to gain and/or upgrade skills to incorporate acute ischemic stroke care into their practice.

1 Oct 2009

Alexza enters into agreement with institutional investors to raise $19.7 million

Alexza Pharmaceuticals, Inc. announced today that it has entered into a definitive agreement with various institutional investors to raise $19.7 million in a private placement of its common stock.

1 Oct 2009

Solvay's decision to sell its Pharmaceuticals Sector does not affect Girindus

Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay's decision to sell its Pharmaceuticals Sector to Abbott. Girindus is a member of Solvay Organics, which is part of the Chemicals Division of the Solvay Group and is therefore completely separate from the Pharmaceuticals Division.

1 Oct 2009

Hospira acquires global rights to biogeneric filgrastim from PLIVA

Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska d.o.o. (Zagreb, Croatia) (ZSE: PLVA-R-A), a move that will help extend Hospira's reach and vertical integration in biogenerics. Financial terms of the agreement were not disclosed.

1 Oct 2009

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy.

1 Oct 2009

Altered state physiology drug development platform to treat an array of human conditions

David H. Fater, CEO of Vicor Technologies, Inc., today announced that on July 23, 2009, the Australian Patent Office issued it a Deed of Letters Patent for its altered state physiology drug development platform. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

1 Oct 2009

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger.

1 Oct 2009

House leaders work to bring health bill below $900 billion

Speaker Nancy Pelosi says House Democrats have a plan to get the cost of their health bill below $900 billion over 10 years, the amount requested by President Barack Obama.

1 Oct 2009

Obama's turn to retake lead on health reform nears

President Obama's turn to step to the lead regarding the shape of health reform legislation is quickly approaching.

1 Oct 2009

Antidepressant amitriptyline works just as well as placebo for children with gastrointestinal disorders

When used "off-label," the antidepressant amitriptyline works just as well as placebo in treating pain-predominant gastrointestinal disorders in children, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. To view this article's video abstract, go to the AGA's YouTube Channel at www.youtube.com/AmerGastroAssn.

1 Oct 2009

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes repayable no later than October 31, 2012 in the total amount of $155 million.

1 Oct 2009

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea Biosciences, Inc. announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

1 Oct 2009

Pharmaceuticals News and Research

Fovea Pharmaceuticals to sell 100% of its share to Sanofi-Aventis

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Cutting Edge Information hopes to see ill patients have speedier access to potential cures

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

USPTO allows BioMarin's claims covering the approved administration of sapropterin dihydrochloride with food

PharmaNova to announce new technology breakthroughs at the 2009 AAPS annual meeting

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

Society of Interventional Radiology offers intensive five-day course

Alexza enters into agreement with institutional investors to raise $19.7 million

Solvay's decision to sell its Pharmaceuticals Sector does not affect Girindus

Hospira acquires global rights to biogeneric filgrastim from PLIVA

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

Altered state physiology drug development platform to treat an array of human conditions

Raptor and TorreyPines Therapeutics announce merger completion

House leaders work to bring health bill below $900 billion

Obama's turn to retake lead on health reform nears

Antidepressant amitriptyline works just as well as placebo for children with gastrointestinal disorders

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

A guide to density measurement excellence eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring